ID: ALA5201325

Max Phase: Preclinical

Molecular Formula: C21H18N4O

Molecular Weight: 342.40

Associated Items:

Representations

Canonical SMILES:  Cc1nn(-c2ccccc2)c(C)c1C(=O)Nc1ccc2ccccc2n1

Standard InChI:  InChI=1S/C21H18N4O/c1-14-20(15(2)25(24-14)17-9-4-3-5-10-17)21(26)23-19-13-12-16-8-6-7-11-18(16)22-19/h3-13H,1-2H3,(H,22,23,26)

Standard InChI Key:  VBYNHIJGYCRJLN-UHFFFAOYSA-N

Associated Targets(Human)

Protein Wnt-3a 90 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 342.40Molecular Weight (Monoisotopic): 342.1481AlogP: 4.29#Rotatable Bonds: 3
Polar Surface Area: 59.81Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 2.39CX LogP: 4.23CX LogD: 4.23
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.60Np Likeness Score: -1.90

References

1. Ai Y, Sakamuru S, Imler G, Xia M, Xue F..  (2022)  Improving the solubility and antileukemia activity of Wnt/β-catenin signaling inhibitors by disrupting molecular planarity.,  69  [PMID:35777269] [10.1016/j.bmc.2022.116890]

Source